The advent of biosimilars, such as adalimumab-adbm (Cyltezo), represents
a significant advancement in the management and treatment of chronic
inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and
chronic plaque psoriasis. However, immunogenicity, which can affect the
efficacy and safety of these treatments, remains a critical concern.
This study compares the immunogenicity of adalimumab-adbm with that of
its reference product (Humira) to provide valuable insights for healthcare
professionals in their clinical practice.
Do Biosimilars Offer Comparable Immunogenicity to Their Reference
Products?
The immunogenicity of adalimumab-adbm was compared with its reference
product in patients with moderate-to-severe rheumatoid arthritis, Crohn's
disease, and chronic plaque psoriasis.
Immunogenicity was evaluated based on two key criteria:
- Anti-drug
antibodies (ADAs): Measured at defined intervals.
- Neutralizing
antibodies (nAbs): Studied for their impact.
The results showed differences in ADA and nAb levels between the
treatments, but without a significant impact on clinical efficacy. The
primary clinical responses, i.e., the main therapeutic objectives of the
trials, were found to be comparable between the two groups.
It is also noteworthy that the incidence of antibodies varies
by disease. The incidence of ADAs is lower in rheumatoid arthritis—thanks
to the use of methotrexate—intermediate in Crohn's disease, and higher in
chronic plaque psoriasis due to the frequent absence of background therapy.
Confirmed Biosimilarity and Future Opportunities
The findings of these trials confirm the biosimilarity between
adalimumab-adbm and its reference product, demonstrating comparable
immunogenicity and maintained clinical efficacy. These data support the
adoption of biosimilars as interchangeable alternatives, paving the way for
expanded treatment options, particularly for patients with rheumatoid
arthritis, Crohn's disease, and chronic plaque psoriasis.
